PUT CHEMO TO THE TEST
Do you really need chemotherapy for your early-stage breast cancer? The Oncotype DX test is the only way to know if you will benefit from chemotherapy or not.*
COUNT ME IN
OF MORE THAN 1.5 MILLION WOMEN†
WHO HAVE PUT CHEMO TO THE TEST
About Genomic Testing – The Key to Understanding Your Cancer
Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. The Oncotype DX Breast Recurrence Score test is the only test proven to predict chemotherapy benefit for early stage HR-positive, HER2-negative, node positive/negative breast cancer patients . The test provides a personalized score based on your tumor’s genomic profile that can help tailor treatment decisions for your breast cancer. Watch the video to learn more about genomic testing and the Oncotype DX test.
Transforming The Treatment of Breast Cancer
With the results of the TAILORx and RxPONDER trials, both published in the New England Journal of Medicine, the Oncotype DX Breast Recurrence Score test can now be used to determine with precision the benefit of chemotherapy for both node-negative and node-positive early-stage breast cancer patients. Watch the video to learn more about how published data from the RxPONDER trial helps inform chemotherapy treatment decisions for HR-positive, HER2-negative breast cancer patients.
